Gold prices hold sharp gains as soft US jobs data fuels Fed rate cut bets
On Wednesday, Cantor Fitzgerald reaffirmed its Overweight rating and $47.00 price target for Astria Therapeutics (NASDAQ:ATXS) shares, representing significant upside potential from the current price of $3.99. According to InvestingPro data, analyst targets range from $16 to $47, with a strong buy consensus rating of 1.22. The biotechnology firm’s focus remains on its leading drug candidate, navenibart, an anti-kallikrein antibody designed as a prophylactic therapy for Hereditary Angioedema (HAE). Following the company’s first-quarter earnings for 2025, the firm’s analysts expressed continued confidence in the potential of navenibart to outperform existing treatments for HAE.
According to Cantor Fitzgerald, the anticipated topline data from Astria’s ongoing Phase 3 study, which is currently recruiting participants, is expected to be released in early 2027, less than 24 months from now. The firm’s analysts underscore the significance of this upcoming milestone in the drug’s development pathway.
Astria Therapeutics appears to be in a stable financial position to support its operations and clinical trials. As of the first quarter of 2025, the company reported approximately $295 million in capital, which, based on company guidance, should fund operations through the middle of 2027. InvestingPro analysis indicates the company holds more cash than debt and maintains a healthy current ratio of 17.39, though it is quickly burning through cash. Get access to 8 more exclusive InvestingPro Tips to better understand ATXS’s financial health. This financial runway is crucial as Astria continues to invest in the development of navenibart and moves closer to potentially bringing the therapy to market.
The positive outlook from Cantor Fitzgerald is rooted in the belief that navenibart will offer superior efficacy and a longer duration of action compared to other prophylactic therapies currently available for HAE patients. The successful development and approval of navenibart could represent a significant advancement in the treatment of this rare and potentially life-threatening condition.
Astria Therapeutics, with the backing of Cantor Fitzgerald’s analysis, is poised to continue its efforts in the HAE therapeutic space, with the goal of providing an improved prophylactic option for patients suffering from the disease. The market will be closely watching as the company progresses towards the release of its Phase 3 study data and further development milestones. The stock has faced significant pressure, declining 61.35% over the past six months, and InvestingPro analysis suggests the stock is currently undervalued, with a Fair Value assessment indicating potential upside.
In other recent news, Astria Therapeutics has reported progress in its clinical trials for navenibart, a potential treatment for hereditary angioedema (HAE). The company has published results from its Phase 1a trial, which indicate that navenibart could be administered every three to six months, offering a long-acting treatment option. This trial showed that the drug had a mean half-life of 82 to 105 days at doses of 300 mg or higher and was well-tolerated with no serious adverse events reported. Astria is also advancing its Phase 3 ALPHA-ORBIT trial, with results expected in early 2027, and is preparing to release long-term follow-up data from the Phase 1b/2 trial in mid-2025.
JMP Securities has maintained a Market Outperform rating for Astria Therapeutics, with a price target of $26, citing the company’s effective progression in its clinical trials. Additionally, Cantor Fitzgerald has initiated coverage on Editas Medicine (NASDAQ:EDIT), setting a $47 price target and an Overweight rating, based on the potential of navenibart in the HAE treatment landscape. The analysts noted that navenibart’s less frequent dosing schedule could offer significant convenience over existing therapies. Astria is also developing STAR-0310, an OX40 antagonist for atopic dermatitis, with initial clinical data expected in the third quarter of 2025. These developments highlight Astria Therapeutics’ ongoing efforts to address unmet medical needs in the biopharmaceutical market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.